Reviewing Echo Therapeutics (ECTE) & Vision Sciences (CGNT)

Echo Therapeutics (OTCMKTS: ECTE) and Vision Sciences (NASDAQ:CGNT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.

Institutional and Insider Ownership

14.5% of Vision Sciences shares are held by institutional investors. 7.0% of Echo Therapeutics shares are held by insiders. Comparatively, 62.7% of Vision Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Echo Therapeutics and Vision Sciences, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Echo Therapeutics 0 0 0 0 N/A
Vision Sciences 0 2 1 0 2.33

Vision Sciences has a consensus target price of $4.58, suggesting a potential upside of 19.05%. Given Vision Sciences’ higher possible upside, analysts clearly believe Vision Sciences is more favorable than Echo Therapeutics.

Risk & Volatility

Echo Therapeutics has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500. Comparatively, Vision Sciences has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500.

Earnings & Valuation

This table compares Echo Therapeutics and Vision Sciences’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Echo Therapeutics N/A N/A -$22.19 million N/A N/A
Vision Sciences $56.32 million 4.16 -$880,000.00 ($0.01) -385.00

Vision Sciences has higher revenue and earnings than Echo Therapeutics.

Profitability

This table compares Echo Therapeutics and Vision Sciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Echo Therapeutics N/A N/A N/A
Vision Sciences -1.57% -1.39% -1.21%

Summary

Vision Sciences beats Echo Therapeutics on 6 of the 10 factors compared between the two stocks.

About Echo Therapeutics

Echo Therapeutics, Inc. engages in the development of transdermal skin permeation and diagnostic medical devices for wearable-health consumer and diabetes outpatient markets. It is developing continuous glucose monitoring (CGM) system, a needle-free wireless continuous glucose monitoring system in a hospital setting in the European Union. The company has a licensing agreement with Ferndale Pharma Group, Inc. to develop, manufacture, distribute, and market devices for skin preparation prior to the application of topical anesthetics or analgesics prior to a range of needle-based medical procedures in North America, the United Kingdom, South America, Australia, New Zealand, Switzerland, and other portions of the European Community. In addition, it has a license agreement with Handok Pharmaceuticals Co., Ltd. to develop, use, market, import, and sell CGM to medical facilities and individual consumers in South Korea; and a license, development, and commercialization agreement with Medical Technologies Innovation Asia, Ltd to research, develop, manufacture, and use CGM in the People's Republic of China, Hong Kong, Macau, and Taiwan. The company was founded in 1989 and is headquartered in Iselin, New Jersey.

About Vision Sciences

Cogentix Medical, Inc., a medical device company, designs, develops, manufactures, and markets fiberoptic and video endoscopy products under the PrimeSight brand worldwide. The company offers endoscopes, such as cystoscopes, laryngoscopes, transnasal esophagoscopes, and bronchoscopes for medical use; and borescopes for industrial use, as well as digital processing units for medical use. It also provides EndoSheath Protective Barrier, a sterile, single-use microbial barrier for use with flexible endoscopes. In addition, the company offers Urgent PC System, a neuromodulation system that delivers percutaneous tibial nerve stimulation for office-based treatment of overactive bladder; and Macroplastique, an injectable, urethral bulking agent for the treatment of adult female stress urinary incontinence. Further, it provides Macroplastique products for the treatment of vesicoureteral reflux; PTQ Implants to treat fecal incontinence; Urgent PC System for the treatment of fecal incontinence; and VOX Implants to enhance speech and swallowing function in patients with unilateral vocal cord paralysis. Additionally, the company distributes wound care products in the Netherlands and the United Kingdom. Cogentix Medical, Inc. sells its products through a direct sales force and a network of distributor organizations. The company was founded in 1987 and is headquartered in Minnetonka, Minnesota.

Receive News & Ratings for Echo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Echo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply